Ibio Stock Price, News & Analysis

iBio licenses a novel antibody targeting regulatory T cells through a worldwide exclusive agreement with RubrYc Therapeutics for RTX-003, enhancing its oncology pipeline. The partnership includes options for additional antibodies from RubrYc's AI-based platform. iBio has acquired an equity stake in RubrYc and is committed to further investment. Preclinical data shows RTX-003 effectively depletes Tregs without blocking IL-2 signaling, promising strong anti-tumor responses. iBio plans to advance RTX-003 to clinical studies as IBIO-101, with IND-enabling studies expected by mid-2022.

iBio announced positive results from preclinical studies of its COVID-19 vaccine candidate, IBIO-202, which targets the nucleocapsid protein of SARS-CoV-2. The studies revealed a strong antigen-specific memory T-cell response, suggesting that IBIO-202 may complement existing spike protein-directed vaccines by enhancing durability against emerging variants. The N protein is more conserved, showing 90% amino acid homology, and can induce T-cell proliferation. Ongoing characterization studies aim to further explore the vaccine's potential.

iBio, a biotech innovator, announced the addition of three anti-cancer targets to its pipeline. This follows its recent drug discovery capability expansion via the FastPharming Protein Expression System. iBio has partnered with FairJourney Biologics for antibody optimization, utilizing their novel display technologies. The collaboration aims to enhance the development of differentiated cancer therapeutic antibodies and improve the process of moving from concept to clinical trials. iBio leverages Glycaneering Technologies to optimize antibody-dependent cell-mediated cytotoxicity.

iBio, Inc. (NYSEA:IBIO) has appointed Evert (Eef) Schimmelpennink to its Board of Directors, effective immediately. Schimmelpennink brings over 20 years of experience in corporate development and biopharmaceutical operations, previously serving as CEO of Pfenex Inc., which was acquired for $516 million in 2020. His expertise aligns with iBio's strategy to enhance its drug discovery capabilities and leverage its patented FastPharming System for efficient biopharmaceutical development. This leadership transition aims to catalyze growth and innovative solutions in addressing healthcare needs.

iBio, a biotech innovator and biologics contract manufacturer, will present a business update at the UBS Global Healthcare Virtual Conference on May 26, 2021, at 4:00 p.m. Eastern Time. This presentation underscores iBio's commitment to advancing its plant-based biologics manufacturing, particularly through its FastPharming® System, which enables rapid delivery of monoclonal antibodies and vaccines. The event will be webcast live and available for later viewing on iBio's website under the Investors section.

iBio reported fiscal Q3 2021 revenues of approximately $0.8 million, up from $0.1 million year-over-year, with a gross profit of $0.3 million. The net loss attributable to stockholders was about $7.7 million, or $0.04 per share, compared to a $4.7 million loss in Q3 2020. iBio is advancing its COVID-19 vaccine candidates IBIO-201 and IBIO-202 while planning to establish drug discovery capabilities in San Diego targeting monoclonal antibodies. The company also expanded its Bioanalytical Services and expects sufficient resources to fund operations through March 2023.

iBio, Inc. (NYSEA:IBIO) announced that it will report its fiscal 2021 third quarter financial results on May 17, 2021, before the market opens. A conference call hosted by iBio management will follow at 8:00 a.m. Eastern Time to discuss these results. The event will be accessible via live and archived webcasts on the company's website. iBio specializes in plant-based biologics manufacturing through its FastPharming® System, providing advanced recombinant protein design and contract manufacturing services, among other biopharmaceutical developments.

iBio, Inc. (NYSEA:IBIO) announced progress on its vaccine candidates IBIO-201 and IBIO-202, which target SARS-CoV-2. IBIO-201 has completed IND-enabling toxicology studies with no adverse effects reported. Meanwhile, IBIO-202, focusing on the N protein, aims to provide broader protection against variants and utilizes iBio's patented LicKM booster. The company is also pursuing multiple subunit vaccines. Four provisional patents supporting IBIO-202 have been filed, with preclinical results anticipated in early Q1 FY2022, highlighting iBio's commitment to advancing its vaccine development initiatives.

iBio, Inc. (NYSEA:IBIO) has settled its lawsuit with Fraunhofer USA, confirming its ownership of specific intellectual property for plant-based biopharmaceutical production. The settlement includes a fully paid-up license granted to Fraunhofer USA for recombinant protein manufacturing technologies. Compensation for legal fees was provided alongside future cash payments scheduled for March 2022 and March 2023. This resolution assures iBio's clients of ongoing support in developing plant-based biologics through its FastPharming® Technologies.